Treatment Approaches for Refractory Mycoplasma genitalium Infection

Area of Science:

• Infectious Diseases
• Microbiology
• Antimicrobial Resistance

Background:

• Mycoplasma genitalium is a significant sexually transmitted infection (STI) linked to urethritis, cervicitis, and pelvic inflammatory disease.
• Management is challenging due to escalating antimicrobial resistance, particularly to macrolides, fluoroquinolones, and dual-class resistance.
• The absence of a cell wall in M. genitalium restricts treatment options to macrolides, tetracyclines, and fluoroquinolones.

Purpose of the Study:

• To review current standard-of-care treatment strategies for Mycoplasma genitalium infections.
• To explore emerging therapeutic approaches for resistant or refractory M. genitalium cases.
• To identify critical gaps in diagnostic capabilities, clinical trial data, and antimicrobial development for STIs.

Main Methods:

• Literature review of contemporary standard-of-care treatments.
• Analysis of emerging therapeutic strategies for resistant M. genitalium.
• Identification of gaps in diagnostic testing and clinical research.

Main Results:

• Current guidelines recommend staged, resistance-guided therapy, but access to resistance testing is inconsistent.
• Fluoroquinolone resistance testing is largely unavailable in routine practice.
• Correlations between resistance markers and clinical outcomes remain incomplete.

Conclusions:

• Refractory Mycoplasma genitalium infections present a common and challenging clinical scenario due to widespread antimicrobial resistance.
• Inconsistent diagnostic capacity and incomplete clinical data hinder effective management.
• There is a critical need for improved diagnostics, robust clinical trial data, and novel antimicrobial agents for STIs.